Highlights

  • QIAGEN launches QIAsymphony Connect, enhancing speed, traceability, and connectivity for labs.
  • Platform supports high-sensitivity applications such as liquid biopsy and MRD monitoring.
  • Collaborations with Element Biosciences and Myriad Genetics advance precision oncology research.

QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard: QIA) announced the launch of QIAsymphony Connect, the next generation of its automated nucleic acid purification platform, at the 2025 Association for Molecular Pathology (AMP) Annual Meeting in Boston.

The new platform builds on the success of over 3,000 global installations of the original QIAsymphony system. QIAsymphony Connect introduces enhanced digital capabilities and optimized workflows for liquid biopsy applications, designed to meet growing laboratory demands for higher precision and throughput.

Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN, stated:

“As labs face increasing pressure to process more complex samples with greater precision and speed, QIAsymphony Connect is designed to help them meet those challenges. Our presence at AMP 2025 highlights our commitment to advancing high-growth areas of sample technologies where QIAGEN is playing a leading role in supporting customers worldwide with novel liquid biopsy applications as well as working with our partners to create innovative advances in precision oncology.”

Next-Generation Automation Features

QIAsymphony Connect delivers multiple upgrades to performance and usability, targeting both diagnostic and research workflows.

Key features include:

  • Superior extraction performance: Enhanced elution technology reduces dead volume, increasing nucleic acid yield.
  • Higher throughput: Supports up to 50% more samples in liquid biopsy protocols.
  • Oncology-focused optimization: Tailored for workflows such as minimal residual disease (MRD) monitoring, improving early detection accuracy.
  • End-to-end traceability: Automated 2D barcode scanning ensures complete tracking of samples and eluates.
  • Seamless digital integration: Compatible with laboratory information management systems (LIMS) and QIAsphere, QIAGEN’s cloud-based remote monitoring platform.

The platform is currently available to selected customers through an early access program, with full commercial release expected by mid-2026. The first-generation QIAsymphony will continue to be available during the transition.

Precision Oncology Partnerships

QIAGEN also announced new data and developments from two collaborations highlighting its Sample to Insight workflows in precision oncology.

A joint workshop with Element Biosciences on November 12 will present early-access data from a study led by Dr. Pinar Uysal-Onganer of the University of Westminster. The study showcases a scalable genomic profiling workflow for breast cancer FFPE samples using QIAseq xHYB Trinity CGP on Element’s Trinity platform. Commercial launch is anticipated in early 2026.

Additionally, early results from QIAGEN’s collaboration with Myriad Genetics Inc. demonstrate high concordance between the QIAseq xHYB HRD Panel and Myriad’s MyChoice® CDx assay for homologous recombination deficiency (HRD) testing. Full commercialization of the QIAseq xHYB HRD Panel (excluding Japan) is also expected in early 2026.

The HRD Panel can be integrated with QIAGEN’s CGP Panel for comprehensive genomic profiling, assessing 724 cancer-related genes and therapy biomarkers including BRCA1/2, HRD, MSI, and TMB.